Register | Login
Intellectual Property Today
RFC Express - Document Management System
2010 Top Trademark Firms
2010 Top Patent Firms
Current Issue

Advertising Opportunities

Click Here

Email A Friend Back to Intellectual Property News

U.S. Patent and Trademark Office Terminates Interference Proceeding in Favor of PDL BioPharma, Inc.

Monday, December 20, 2010

Incline Village, NV -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that on December 15, 2010, the U.S. Patent and Trademark Office (the PTO) terminated its interference proceeding between certain claims of the Company's Queen et al., U.S. Patent No. 5,585,089, (the '089 Patent) and certain pending claims of Adair et al., U.S. Application No. 08/846,658, (the '658 Application) in favor of the Company's '089 Patent. The PTO held that the involved claims in the '658 Application, are not patentable. UCB Pharma S.A. is the assignee of the '658 Application.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed by leading pharmaceutical and biotechnology companies today based on patents which expire in late 2014. For more information, please visit

Back to Intellectual Property News
Looking for...

  © Copyright 2010 Intellectual Property Today
Download Adobe Reader for free